Genetic reduction of group 1 metabotropic glutamate receptors alters select behaviors in a mouse model for fragile X syndrome. - Wikidata - awgldk - TriplyDB

Genetic reduction of group 1 metabotropic glutamate receptors alters select behaviors in a mouse model for fragile X syndrome.

Genetic reduction of group 1 metabotropic glutamate receptors alters select behaviors in a mouse model for fragile X syndrome.

http://www.wikidata.org/entity/Q35125117

about

Emerging pharmacologic treatment options for fragile X syndrome The pathophysiology of fragile X (and what it teaches us about synapses)Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromes Therapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and Back Genetic manipulation of STEP reverses behavioral abnormalities in a fragile X syndrome mouse model.Selective Disruption of Metabotropic Glutamate Receptor 5-Homer Interactions Mimics Phenotypes of Fragile X Syndrome in Mice.Behavioral analysis of male and female Fmr1 knockout mice on C57BL/6 background.From FMRP function to potential therapies for fragile X syndrome.The autism diagnosis in translation: shared affect in children and mouse models of ASD.Genetic reduction of muscarinic M4 receptor modulates analgesic response and acoustic startle response in a mouse model of fragile X syndrome (FXS).Genetic models of sensorimotor gating: relevance to neuropsychiatric disorders.Disrupted Homer scaffolds mediate abnormal mGluR5 function in a mouse model of fragile X syndrome.Acamprosate in a mouse model of fragile X syndrome: modulation of spontaneous cortical activity, ERK1/2 activation, locomotor behavior, and anxiety Fragile X targeted pharmacotherapy: lessons learned and future directions.Reduced phenotypic severity following adeno-associated virus-mediated Fmr1 gene delivery in fragile X mice.Selective role of the catalytic PI3K subunit p110β in impaired higher order cognition in fragile X syndrome.Double Dissociation of the Roles of Metabotropic Glutamate Receptor 5 and Oxytocin Receptor in Discrete Social Behaviors.Synaptic plasticity in mouse models of autism spectrum disorders.Plasticity and mTOR: towards restoration of impaired synaptic plasticity in mTOR-related neurogenetic disorders Development of mavoglurant and its potential for the treatment of fragile X syndrome.Synaptic basis of social dysfunction: a focus on postsynaptic proteins linking group-I mGluRs with AMPARs and NMDARs.The complex genetics in autism spectrum disorders.Pharmacotherapy for Fragile X Syndrome: Progress to Date.Common variants in genes of the postsynaptic FMRP signalling pathway are risk factors for autism spectrum disorders.Altered Connectivity and Synapse Maturation of the Hippocampal Mossy Fiber Pathway in a Mouse Model of the Fragile X Syndrome.Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen.Combination Therapy in Fragile X Syndrome; Possibilities and Pitfalls Illustrated by Targeting the mGluR5 and GABA Pathway Simultaneously.Multiple Behavior Phenotypes of the Fragile-X Syndrome Mouse Model Respond to Chronic Inhibition of Phosphodiesterase-4D (PDE4D).Excess Translation of Epigenetic Regulators Contributes to Fragile X Syndrome and Is Alleviated by Brd4 Inhibition.Mdm2 mediates FMRP- and Gp1 mGluR-dependent protein translation and neural network activity.Sleep/wake physiology and quantitative EEG analysis of the Neuroligin-3 knockout rat model of autism spectrum disorder.Decreased home cage movement and oromotor impairments in adult Fmr1-KO mice.Protein synthesis levels are increased in a subset of individuals with Fragile X syndrome.Of Men and Mice: Modeling the Fragile X Syndrome.Paradoxical effect of baclofen on social behavior in the fragile X syndrome mouse model.

P2860

Q26829152-6493BF9B-9527-40A0-AF81-018E15386F2E Q27010675-5E8423E7-3969-462B-B88B-F301C487C5B9 Q27023257-55ED89F4-00A4-4E52-8C5B-00E40CB369E4 Q27337360-B151FD62-E64A-41C7-BCF8-124CA6815947 Q28261563-A2A283D4-6BFB-4691-BB8A-6BD4F50E96AE Q30376422-73BBD8E1-BE3A-4EB1-A3B6-71DC6F7CE96D Q30403591-58788A5A-44CE-451F-8F33-8F5C1839BE2A Q30410502-29E92377-B544-4FE4-9568-8FB2396BCA5B Q30453436-39C2E7E8-033F-4ADE-8E0B-3EDFF11D27BF Q30457688-39348BE3-C332-44EB-A7CB-7CC129AC57E4 Q30459497-AEB2D241-2823-4E1C-BC83-D137962F76D0 Q30505749-4DC84EF9-4C0C-485F-8D2A-B76369FFB528 Q30855390-AE66A335-3A3F-4225-BD3C-6D38DFB346A0 Q33785983-140774E2-5D26-4732-8E34-9518B9687F2C Q34499370-927C3C77-E3AB-4D48-BCBD-4EE92AF0941A Q35588887-C5699113-8B7E-4A23-B4D9-B5C762AAC899 Q35960336-15CF9220-FADD-414B-A21E-DB5522A31229 Q36479094-C66482FD-2BCA-4071-B665-48126A8AB3AE Q38012453-AE8723B6-EB7F-421D-8D72-7B273CFD7BBE Q38164021-123EE47C-B779-4F20-98A5-1AE1BEC3EDFE Q38203028-3DBEDD25-77AB-4E06-BAE7-BC8D26518959 Q38579867-3B45ACEA-C365-4148-B4E0-5A5B04A10D31 Q38726962-67D1FE4F-00FB-4307-8851-9C99EF72549F Q39268882-61F5840C-2250-4127-90F3-C70075FDAEC5 Q40376074-69E2877D-E0B0-4840-B533-DB1F96DFF037 Q42512974-8D38943D-E0A0-42FD-A910-626EEC661133 Q47112165-CB65DE9D-AA1B-4BE0-BCF4-7C12F59F98D4 Q47118227-2B1296D9-C3DB-4632-B24F-E3D674757496 Q47132107-15864495-2AA5-451C-929C-7D381CB2F411 Q47601432-BFA99315-99CE-484C-BAC4-3537CE21F7AA Q47680079-949DDFD8-8616-4701-8567-B1FF0488A376 Q47795409-B9AEE769-E2A6-45D4-9B96-42B9300E123D Q51733403-B25CD8F4-9EE6-4FAF-8E90-1668639E9C8B Q53422584-9A0967C5-4999-4FBD-8D99-851CDB5B7990 Q55155951-2EEAE960-70DD-43E2-A79F-A63CCEE626AF

P2860

Genetic reduction of group 1 metabotropic glutamate receptors alters select behaviors in a mouse model for fragile X syndrome.

http://www.wikidata.org/entity/Q35125117

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Genetic reduction of group 1 m ...... model for fragile X syndrome.

@ast

Genetic reduction of group 1 m ...... model for fragile X syndrome.

@en

type

label

Genetic reduction of group 1 m ...... model for fragile X syndrome.

@ast

Genetic reduction of group 1 m ...... model for fragile X syndrome.

@en

prefLabel

Genetic reduction of group 1 m ...... model for fragile X syndrome.

@ast

Genetic reduction of group 1 m ...... model for fragile X syndrome.

@en

P1433

Q35125117-158053E7-2911-45C3-8634-97E8301E0611

P1476

Q35125117-397D5E21-123F-4F25-B12B-DFEA5780BE29

P2093

Q35125117-60C52DE9-A260-4ADC-992F-EBC591ACBB7F

Q35125117-838700D9-5003-4DDB-AF07-EF346C53AB68

Q35125117-A07C6ABC-6672-4EE5-B2AA-336B63B83210

Q35125117-A8FA522F-7AF1-482F-93E2-6441BD0C49E3

Q35125117-DEDFAD58-FA0B-4FD6-A018-977C67293955

Q35125117-E96D18CB-3229-4EB2-B9C2-916C1D2DB437

P2860

Q35125117-0130173B-2F11-4EB8-88FD-9A6170522B66

Q35125117-02414B61-67D6-472D-961F-69B66FD9D01C

Q35125117-046E297D-9A14-41DA-9FB4-7690FFC5363D

Q35125117-066D7E3F-F01F-4125-8FD6-CE9F2B70848C

Q35125117-0891B775-F24B-408E-BED6-A2FE0F10F78F

Q35125117-0B6BF33A-797E-42D1-A99E-748D47D6794F

Q35125117-11B00F69-C8C1-445E-B6E4-35FCFD7F5888

Q35125117-1253A5B8-4153-4B61-8B15-8D9D66A415E0

Q35125117-1309FFB0-E2EB-4E4A-B900-553DEAAA375B

Q35125117-14562B3D-3E64-4C6F-A141-636C194DB194

P304

Q35125117-0885CBD2-1D37-45AB-9B72-CD72AD43E9DA

P31

Q35125117-518D1B80-7A9A-4349-9798-E1BD91320FCA

P356

Q35125117-3877D56C-A411-47CA-9DDE-6AA49EEE8716

P407

Q35125117-0169F48B-B67F-4E9A-9FF4-63115879788C

P433

Q35125117-E099DE8B-395E-4469-AF04-0B489D2FEDF4

P478

Q35125117-A78F6116-BD1C-4C30-BB08-E514190C1E94

P577

Q35125117-6DB6B8D1-FC4A-4CC6-95ED-F9A8CD851E1E

P5875

Q35125117-270F1B59-BA39-479B-97BC-348571CAEA8C

P698

Q35125117-E774AD65-7B79-4826-B4FB-CB747800CE38

P932

Q35125117-35264D9B-85B5-48BF-BECD-38E3A743C02B

P356

J.BBR.2011.04.049

P1433

Behavioural Brain Research

P1476

Genetic reduction of group 1 m ...... model for fragile X syndrome.

@en

P2093

Alexia M Thomas

http://www.w3.org/2001/XMLSchema#string

Deanna Graham

http://www.w3.org/2001/XMLSchema#string

Jennifer R Perkins

http://www.w3.org/2001/XMLSchema#string

Lisa A Yuva-Paylor

http://www.w3.org/2001/XMLSchema#string

Nghiem Bui

http://www.w3.org/2001/XMLSchema#string

Richard Paylor

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanism-based approaches to treating fragile X

Correction of fragile X syndrome in mice.

Altered synaptic plasticity in a mouse model of fragile X mental retardation

Blockade of mGluR1 receptor results in analgesia and disruption of motor and cognitive performances: effects of A-841720, a novel non-competitive mGluR1 receptor antagonist

Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety

Modifying behavioral phenotypes in Fmr1KO mice: genetic background differences reveal autistic-like responses.

Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist

Glutamate metabotropic receptors as targets for drug therapy in epilepsy

Dysregulated metabotropic glutamate receptor-dependent translation of AMPA receptor and postsynaptic density-95 mRNAs at synapses in a mouse model of fragile X syndrome

Deletion of FMR1 in Purkinje cells enhances parallel fiber LTD, enlarges spines, and attenuates cerebellar eyelid conditioning in Fragile X syndrome

P304

310-321

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BBR.2011.04.049

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

223

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51125565

http://www.w3.org/2001/XMLSchema#string

P698

21571007

http://www.w3.org/2001/XMLSchema#string

P932

3142659

http://www.w3.org/2001/XMLSchema#string